Ghassan K. Abou-Alfa, Stephen Lam Chan, Lipika Goyal, Najib Ben Khaled, Masatoshi Kudo, Angela Lamarca, Philippe Merle, Lorenza Rimassa, Changhoon Yoo, Yujie Zhong, Xiao Qu, Jinfeng Xiang, Jian Zhou. "ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.tps612